AZD0284 / AstraZeneca - LARVOL DELTA

AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2. (PubMed, J Med Chem) - "Inverse agonists of the nuclear receptor RORC2 have been widely pursued as a potential treatment for a variety of autoimmune diseases. In two preclinical in vivo studies, compound 20 reduced thymocyte numbers in mice and showed dose-dependent reduction of IL-17A containing γδ-T cells and of IL-17A and IL-22 RNA in the imiquimod induced inflammation model. Based on these data and a favorable safety profile, 20 was progressed to phase 1 clinical studies."

Journal • Immunology • Inflammation • IL17A • IL22

Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis (clinicaltrials.gov) - P1b; N=25; Not yet recruiting; Sponsor: AstraZeneca

Clinical • New P1 trial • Dermatology • Immunology • Psoriasis • IL17A

Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis (clinicaltrials.gov) - P1b; N=25; Suspended; Sponsor: AstraZeneca; Recruiting ➔ Suspended

Clinical • Trial suspension • Dermatology • Immunology • Psoriasis • IL17A

Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis (clinicaltrials.gov) - P1b; N=9; Terminated; Sponsor: AstraZeneca; N=25 ➔ 9; Suspended ➔ Terminated; The study is temporarily suspended due to preclinical findings that are currently under evaluation

Clinical • Enrollment change • Trial termination • Dermatology • Immunology • Psoriasis • IL17A

Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis (clinicaltrials.gov) - P1b; N=25; Recruiting; Sponsor: AstraZeneca; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Dermatology • Immunology • Psoriasis • IL17A

Pharmacokinetics, Pharmacodynamics, and Safety of the Inverse Retinoic Acid-Related Orphan Receptor γ Agonist AZD0284. (PubMed, Br J Clin Pharmacol) - "AZD0284 was well tolerated, rapidly and dose-dependently absorbed, and reduced stimulated IL-17A release after single and multiple dosing. The results of this study support further clinical development of AZD0284."

Clinical • Journal • PK/PD data • IL17A